See the Complete Picture.
Published loading...Updated

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

Summary by PharmaVOICE
With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PharmaVOICE broke the news in on Thursday, May 8, 2025.
Sources are mostly out of (0)